Document Type

Conference Proceeding

Publication Date


Publication Title

J Dtsch Dermatol Ges


Introduction: Calcipotriol (50 mcg/g CAL) and betamethasone dipropionate (0.5 mg/g BDP) cream (CAL/BDP cream) is a novel topical treatment for plaque psoriasis. CAL/BDP cream is based on PAD™ Technology, which in a single product enables a combination of efficacy, safety and patient satisfaction. Here, we present data from a pivotal phase 3 trial demonstrating substantial and clinically meaningful improvement of itch in patients with psoriasis.

Methods: Head-to-head, Phase 3, randomized, multicenter, investigator-blind, parallel-group trial comparing the efficacy and safety of CAL/BDP cream vs vehicle and active comparator (CAL/BDP gel/Topical Suspension (TS)) in adults with psoriasis. Itch evaluation: 11-point peak pruritus numeric rating scale (NRS). Itch reduction evaluation: absolute change in peak pruritus NRS score from baseline, and responder analysis defining itch treatment success as at least 4 points improvement in peak pruritus NRS score from baseline. A total of 796 patients at 55 clinical sites across the United States were enrolled; 626 patients out of 796 had a peak pruritus NRS score of at least 4 at baseline. Patients applied study medication once daily for up to 8 weeks.

Results: At week 4, CAL/BDP cream showed superior reduction of peak pruritus NRS score vs vehicle (3.5 vs 1.1 points of improvement; p < 0.0001). At weeks 1 and 8, CAL/BDP cream also demonstrated significant reduction in peak pruritus NRS score compared with vehicle (p < 0.0001) and at week 8 compared with CAL/BDP gel/TS (p < 0.05). Among patients who had at least a peak pruritus NRS score of 4 at baseline, there was a higher patient proportion achieving a clinically relevant improvement of at least 4 points from baseline to week 4 in the CAL/BDP cream group (60.3 %) vs vehicle (21.4 %) (p<0.0001). CAL/BDP cream further demonstrated a significantly greater proportion of patients achieving at least 4 points improvement in peak pruritus NRS score during week 1 of treatment in comparison to CAL/BDP gel/ TS (44.0 % vs 36.9 %; p = 0.0241), thereby underlining the rapid CAL/BDP cream onset of action.

Conclusions: Itch is a plaque psoriasis key symptom. PAD™ Technology based CAL/BDP cream, a novel topical treatment of psoriasis, demonstrated a significant improvement of the proportion of patients achieving a minimum 4-point improvement on the peak pruritus NRS score at week 4.



First Page




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.